Published in Am J Clin Oncol on October 01, 2003
Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression. Cancer Biol Ther (2015) 0.81
Renal medullary carcinoma: unsuspected diagnosis at stone protocol CT. Emerg Radiol (2007) 0.80
Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. Nat Rev Urol (2010) 0.79
Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study. J R Soc Med (2016) 0.77
Renal medullary carcinoma: case report of an aggressive malignancy with near-complete response to dose-dense methotrexate, vinblastine, Doxorubicin, and Cisplatin chemotherapy. Case Rep Oncol Med (2014) 0.75
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest (2003) 16.67
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 8.98
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res (2012) 3.36
Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell (2005) 2.98
A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science (2013) 2.86
Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science (2009) 2.51
Chromatin and sequence features that define the fine and gross structure of genomic methylation patterns. Genome Res (2010) 2.25
BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res (2008) 2.06
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol (2012) 2.04
Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol (2002) 1.53
Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci U S A (2009) 1.45
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res (2009) 1.43
BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol (2007) 1.43
Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest (2002) 1.36
Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol (2006) 1.31
Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res Treat (2011) 1.22
CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology (2006) 1.20
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol (2014) 1.20
A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer (2011) 1.14
Duodenal intraepithelial lymphocytosis with normal villous architecture: common occurrence in H. pylori gastritis. Mod Pathol (2005) 1.08
Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol (2007) 1.07
The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun (2004) 1.02
Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila) (2012) 1.01
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. Clin Cancer Res (2010) 1.00
Evaluation of 4-aminobiphenyl-DNA adducts in human breast cancer: the influence of tobacco smoke. Carcinogenesis (2003) 1.00
Core needle biopsy as a diagnostic tool to differentiate phyllodes tumor from fibroadenoma. Arch Surg (2003) 0.97
Gene promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat (2009) 0.97
PEG10 is a c-MYC target gene in cancer cells. Cancer Res (2006) 0.97
PAX8 and PAX2 immunostaining facilitates the diagnosis of primary epithelial neoplasms of the male genital tract. Am J Surg Pathol (2011) 0.96
Mutations in p53, p53 protein overexpression and breast cancer survival. J Cell Mol Med (2008) 0.96
Molecular epidemiologic studies of polycyclic aromatic hydrocarbon-DNA adducts and breast cancer. Environ Mol Mutagen (2002) 0.95
Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest (2014) 0.94
Immunohistochemical analysis for cytokeratin 7, KIT, and PAX2: value in the differential diagnosis of chromophobe cell carcinoma. Am J Clin Pathol (2007) 0.94
Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer Epidemiol Biomarkers Prev (2004) 0.94
Genomewide scan for loss of heterozygosity and chromosomal amplification in breast carcinoma using single-nucleotide polymorphism arrays. Cancer Genet Cytogenet (2008) 0.93
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 0.92
Isolation of native human monoclonal autoantibodies to breast cancer. Hybrid Hybridomics (2002) 0.91
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother Pharmacol (2013) 0.91
Associations between polycyclic aromatic hydrocarbon-related exposures and p53 mutations in breast tumors. Environ Health Perspect (2009) 0.90
Oral contraceptive use and cyclin D1 overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev (2002) 0.88
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemother Pharmacol (2014) 0.87
Cancer outcomes at the Hufeland (complementary/alternative medicine) klinik: a best-case series review. Integr Cancer Ther (2005) 0.86
Cyclin D1 overexpression is associated with estrogen receptor expression in Caucasian but not African-American breast cancer. Anticancer Res (2005) 0.85
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs (2014) 0.84
The influence of one-carbon metabolism on gene promoter methylation in a population-based breast cancer study. Epigenetics (2011) 0.84
Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cells. Clin Cancer Res (2004) 0.84
Risk factors for uncommon histologic subtypes of breast cancer using centralized pathology review in the Breast Cancer Family Registry. Breast Cancer Res Treat (2012) 0.84
P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res (2005) 0.84
Gene expression profiling and functional activity of human dendritic cells induced with IFN-alpha-2b: implications for cancer immunotherapy. Clin Cancer Res (2003) 0.83
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol (2008) 0.83
Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy. Cancer Chemother Pharmacol (2006) 0.82
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors. Clin Cancer Res (2008) 0.81
Tobacco, alcohol, and p53 overexpression in early colorectal neoplasia. BMC Cancer (2003) 0.81
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemother Pharmacol (2013) 0.81
Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study. Clin Cancer Res (2009) 0.81
Future options for imatinib mesilate-resistant tumors. Expert Opin Investig Drugs (2007) 0.79
p16Ink4a is overexpressed in H. pylori-associated gastritis and is correlated with increased epithelial apoptosis. Helicobacter (2003) 0.78
African-American/White differences in breast carcinoma. Cancer (2005) 0.78
Incidence and clinical significance of lymph node metastasis detected by cytokeratin immunohistochemical staining in ductal carcinoma in situ. Ann Surg Oncol (2005) 0.77
Recurrent oral herpes simplex virus infection presenting as a tongue mass. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2004) 0.77
Invasive ductal carcinoma with fibrotic focus: mammographic and sonographic findings with histopathologic correlation. AJR Am J Roentgenol (2005) 0.77
Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer. Cancer Invest (2014) 0.76
Pubertal outcome in a female with virilizing adrenocortical carcinoma. J Pediatr Endocrinol Metab (2016) 0.75
A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer. Cancer Chemother Pharmacol (2012) 0.75
MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience. Scientifica (Cairo) (2012) 0.75
Comparative study of texture features in OCT images at different scales for human breast tissue classification. Conf Proc IEEE Eng Med Biol Soc (2016) 0.75
FDG PET/CT findings in a rare case of giant fibrovascular polyp of the esophagus harboring atypical lipomatous tumor/well-differentiated liposarcoma. Clin Nucl Med (2014) 0.75
17HSD 2 may be higher in African-American breast cancer and is associated with estrogen receptor-negative tumors. Cancer Genomics Proteomics (2007) 0.75
Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmation. J Clin Pharmacol (2014) 0.75